INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA
Institut
![Foto de INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA](/img/noimage.png)
![Foto de Hospital Universitario Virgen del Rocío](/img/noimage_org.png)
Hospital Universitario Virgen del Rocío
Sevilla, EspañaPublicacions en col·laboració amb investigadors/es de Hospital Universitario Virgen del Rocío (517)
2024
-
ADAMTS13 recovery in acute thrombotic thrombocytopenic purpura after caplacizumab therapy
Blood, Vol. 143, Núm. 18, pp. 1807-1815
-
Avatrombopag plus fostamatinib combination as treatment in patients with multirefractory immune thrombocytopenia
British Journal of Haematology
-
Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma
Clinical Cancer Research, Vol. 30, Núm. 10, pp. 2085-2096
-
Characterization of the plasma proteomic profile of Fabry disease: Potential sex- and clinical phenotype-specific biomarkers
Translational Research, Vol. 269, pp. 47-63
-
Correction in article by Juzga-Corrales et al. “Characteristics and outcomes of the Spanish registry for pediatric patients with bicuspid aortic valve (REVAB)”, Rev Esp Cardiol. 2023;76:961-969 (Revista Española de Cardiología (English Edition) (2024) 77(4) (358–359), (S1885585724000331), (10.1016/j.rec.2023.12.011))
Revista Espanola de Cardiologia
-
Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022
eClinicalMedicine, Vol. 71
-
Efficacy and safety of chemotherapy in young patients with advanced gastroesophageal adenocarcinoma: data from the Spanish AGAMENON-SEOM registry
Gastric Cancer, Vol. 27, Núm. 1, pp. 131-145
-
Erratum: Correction: Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey (Infection (2024) 52 3 (1125-1141))
Infection
-
Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry
Cancer
-
Galectin-3 depletion tames pro-tumoural microglia and restrains cancer cells growth
Cancer Letters, Vol. 591
-
Is there a preferred platinum and fluoropyrimidine regimen for advanced HER2-negative esophagogastric adenocarcinoma? Insights from 1293 patients in AGAMENON–SEOM registry
Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1674-1686
-
Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP
Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1647-1663
-
Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey
Infection, Vol. 52, Núm. 3, pp. 1125-1141
-
Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial
Bone Marrow Transplantation
-
Outcomes after surgical revascularization in diabetic patients
Interdisciplinary cardiovascular and thoracic surgery, Vol. 38, Núm. 2
-
Penetrance of Dilated Cardiomyopathy in Genotype-Positive Relatives
Journal of the American College of Cardiology, Vol. 83, Núm. 17, pp. 1640-1651
-
Persistence, effectiveness and safety of ustekinumab and vedolizumab therapy for complex perianal fistula in Crohn's disease: The HEAL study from GETECCU
Digestive and Liver Disease
-
Ponalfil trial for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: Long-term results
HemaSphere
-
Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis in HLA-Matched and Haploidentical Donor Transplantation for Patients with Hodgkin Lymphoma: A Comparative Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation
Transplantation and Cellular Therapy, Vol. 30, Núm. 2, pp. 210.e1-210.e14
-
Randomised, double-blind, placebo-controlled, parallel-group, multicentric, phase IIA clinical trial for evaluating the safety, tolerability, and therapeutic efficacy of daily oral administration of NFX88 to treat neuropathic pain in individuals with spinal cord injury
Spinal Cord